Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
B.Riley has reaffirmed a Buy rating and a $55.00 price target on TG Therapeutics (TGTX), citing accelerating prescription volumes and stronger-than-expected revenue for the multiple sclerosis therapy Briumvi. Preliminary fourth-quarter U.S. Briumvi sales and full-year 2025 results exceeded estimates, and management provided 2026 U.S. sales guidance…
B.Riley reaffirmed a Buy rating and a $108 price target on Cytokinetics (CYTK), pointing to Myqorzo's potential to take share in the cardiac myosin inhibitor category. The firm's thesis rests on strong market uptake for Bristol Myers Squibb's Camzyos, Myqorzo's simplified REMS and operational advantages, and an addressable patient pool that could a…
Mizuho raised its price target on Willis Towers Watson to $392 from $388 while retaining an Outperform rating, reflecting confidence in the company’s turnaround. The firm raised 2026 and 2027 EPS forecasts, nudged organic growth and margin assumptions higher, and highlighted favorable foreign exchange and a lower anticipated tax rate. Recent quarte…
Barclays, in its European Media - MediaWatch XXXVI report, highlights a group of European media companies that it views as attractively valued despite persistent artificial intelligence worries and an extended sector-wide derating. The bank points to structural resilience to AI disruption, competitive positioning and supportive free cash flow dynam…
BTIG raised its price target on Scorpio Tankers (STNG) to $80 from $75 and kept a Buy rating, citing much stronger-than-expected spot freight rates. Crude tanker rates have averaged about $100,000 year-to-date while MR product spot rates are running near $30,000, supporting elevated sector performance and prompting higher targets across several lis…
Goldman Sachs reiterated its Neutral rating and $7.25 price target on Lumen (NYSE:LUMN) after the company reported fourth-quarter results. The target remains below the share price of $8.46, with Goldman pointing to an investor day on February 25 as a potential catalyst while stressing the need for clearer evidence that management can arrest declini…
BTIG increased its price objective on DHT Holdings to $18 from $16 and kept a Buy rating, pointing to a much stronger-than-expected spot-rate environment for crude and product tankers. The firm also lifted targets on several peers and highlighted factors that could support multiple expansion for shipping companies over the next two years.
Summary: Super Micro Computer (NASDAQ:SMCI) reported fiscal Q2 results that surpassed revenue and earnings expectations, drove management to lift fiscal 2026 revenue guidance, and highlighted sustained demand for AI infrastructure. Despite the top-line outperformance, gross margin compression, heavy revenue concentration in a single customer, and u…
Goldman Sachs trimmed its price target on Take-Two Interactive to $270 from $280 but kept a Buy rating after the publisher reported stronger-than-expected fiscal third-quarter results and raised full-year guidance. The company cited healthy bookings driven by key titles and reiterated a November 19 launch date for Grand Theft Auto VI; analysts rema…
Investment bank Ladenburg Thalmann trimmed its price objective on Portland General Electric (POR) to $42.50 from $43.00 while maintaining a Sell stance, a move that comes as the utility navigates contested regulatory proceedings. The company has proposed a $10 million customer refund in its filing, but regulatory staff have countered with substanti…
Ocular Therapeutix (OCUL) looks like an asymmetric event trade. With AXPAXLI in large registrational programs, strong enrollment signals, rumors of renewed takeover interest from Sanofi, and stretched bearish sentiment, a positive SOL-1 readout could re-rate the stock. Risk is material - trial failure, financing needs, and reimbursement uncertainty…
Talen Energy (TLN) has just added ~2.9 GW of modern gas capacity, expanded digital infrastructure partnerships, and continues to generate healthy free cash flow. The market is fixated on short-term volatility; this trade buys the structural improvement at $340 with a stop at $320 and a $420 target over 180 trading days.
Canaccord Genuity has reaffirmed its Buy rating and $15.00 price target for Hillman Solutions Corp. (NASDAQ:HLMN) ahead of the company’s fourth-quarter results due February 17. The target implies roughly 51% upside from the recent share price of $9.92. Canaccord’s tenth round of customer checks across 51 U.S. locations found winter trends broadly i…
Canaccord Genuity has reiterated a Buy rating on Galaxy Digital (GLXY) with a $50 price target, implying roughly 127% upside from the current $21.98 share price. The firm pointed to the company’s roughly $3 billion of equity capital split across digital assets, data center operations and treasury/corporate, a prior DCF valuation of CoreWeave coloca…
Texas Instruments has reached an agreement to buy Silicon Laboratories for $7.5 billion, paying $231 per share in a transaction designed to bolster TI's position in wireless connectivity chips used in industrial and consumer equipment. The deal, advised exclusively by Goldman Sachs to TI, carries termination fees for both parties and is expected to…
Truist Securities lowered its price target on Varonis Systems to $34 from $42 while keeping a Buy rating, following the cybersecurity firm's quarter that beat revenue and ARR expectations but flagged a $30-50 million headwind to free cash flow and ARR contribution margin in fiscal 2026 tied to the end-of-life of its on-premises customer base.
Jefferies trimmed its price objective for BellRing Brands (BRBR) to $38.00 from $49.00 while retaining a Buy rating, citing intensifying competition and rising input costs in the ready-to-drink shake category. The stock trades well below its 52-week high and shows oversold technical readings. Recent results beat expectations, but management lowered…
BofA Securities lowered its price target on LENZ Therapeutics to $35 from $52 while keeping a Buy rating after the company reported preliminary fourth-quarter net product revenue for its presbyopia eye drop Vizz that beat consensus but signaled a slower market uptake. The brokerage trimmed peak sales and multi-year forecasts, citing earlier launch …
Canaccord Genuity increased its price target on Mercury Systems (MRCY) to $102.00 from $88.00 and maintained a Buy rating after the company reported fiscal second-quarter results that beat expectations on revenue, adjusted EPS and adjusted EBITDA. Mercury delivered $233 million in Q2/26 revenue and reported significant improvements in adjusted prof…
Jefferies reaffirmed a Hold rating on PepsiCo with a $164 price target, noting the company’s refreshed 2026 strategy emphasizing affordability, innovation and sharper execution. The firm highlighted that consumer reaction in the first half of the year will be decisive for the stock’s trajectory. Recent quarter results beat expectations and prompted…
H.C. Wainwright began coverage of Verastem (NASDAQ:VSTM) with a Buy rating and an $18.00 price target, highlighting the company’s KRAS G12D program and the MAPK CLAMP strategy. The firm emphasized VS-7375 as a potentially underappreciated asset, citing early clinical response rates and a mechanism that targets both active and inactive KRAS conforma…
DA Davidson raised its price objective on American Public Education (APEI) to $48 from $43 and kept a Buy rating, saying a recently passed funding bill removes a key overhang tied to the partial government shutdown. The firm pointed to the company’s military education leadership, profit gains at Rasmussen University, and AI-focused degree programs …
Bath & Body Works (BBWI) trades at a discounted multiple (P/E ~6.5, P/FCF ~4.8) while generating nearly $1.0B of free cash flow. The business has to repair a misfired adjacencies strategy and navigate litigation headlines, but a refocus on core fragrance and home categories plus expected margin recovery could produce double-digit total returns over…
Stifel reduced its 12-month price target on Intapp, Inc. (INTA) to $40 from $50 while retaining a Buy rating. The new target implies roughly 36% upside from the current share price of $29.31. The move follows guidance that suggests a modestly lighter second half and coincided with weakness across the software sector that pressured shares in after-h…
BofA Securities upgraded Omnicell (OMCL) from Neutral to Buy and increased its price target to $70 from $53, citing the upcoming launch of the Titan XT automated medication cabinet and the potential for an earnings revision cycle. The upgrade precedes Omnicell's earnings report scheduled for Thursday before market open and follows a string of analy…
